

Table 14.2.2.2: TIME TO INITIAL CONFIRMED ECI BY PRIOR CIDP MEDICATION AT SCREENING - KAPLAN-MEIER

ANALYSIS SET: STAGE A SAFETY

TREATMENT = DUMMYTIGIMOD PH20 SC

	PRIOR CIDP MEDICATION (ACTUAL)		
	(N=72)	(N=34)	(N=50)
25th QUANTILE (95% CI) (DAYS)	22.0 (22.0; 23.0)	22.0 (22.0; 36.0)	30.0 (22.0; 43.0)
50th QUANTILE (95% CI) (DAYS)	29.0 (23.0; 45.0)	43.0 (22.0; 60.0)	71.0 (43.0; 80.0)
75th QUANTILE (95% CI) (DAYS)	70.0 (43.0; NC)	69.0 (57.0; 72.0)	84.0 (73.0; NC)
NUMBER ASSESSED	72	34	50
NUMBER OF EVENTS [1]	40 (55.6%)	25 (73.5%)	30 (60.0%)
NUMBER CENSORED	32 (44.4%)	9 (26.5%)	20 (40.0%)
COMPLETED STAGE A WITH NO CONFIRMED ECI	4 (5.6%)	1 (2.9%)	10 (20.0%)
DISCONTINUED DURING STAGE A	19 (26.4%)	5 (14.7%)	3 (6.0%)
ONGOING IN STAGE A	9 (12.5%)	3 (8.8%)	7 (14.0%)

ECI=EVIDENCE OF CLINICAL IMPROVEMENT; CIDP=CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; NC=NOT CALCULATED.

[1] PARTICIPANTS WITH CONFIRMED ECI DURING STAGE A.

THE DENOMINATOR FOR THE PERCENTAGE CALCULATIONS IS THE TOTAL NUMBER OF PARTICIPANTS IN THE STAGE A SAFETY ANALYSIS SET FOR WHICH ECI COULD BE DETERMINED WITHIN EACH PRIOR CIDP MEDICATION CATEGORY.